Zheng Quan Shi Bao Wang·2025-07-30 12:14Core Viewpoint - The company, Jinhe Biology, reported record-high revenue and profit for the first half of 2025, driven by strong sales in the veterinary pharmaceutical sector, particularly in the overseas market [1] Group 1: Financial Performance - The company achieved a revenue of 1.39 billion yuan, representing a year-on-year growth of 30.45% [1] - The net profit attributable to shareholders reached 138 million yuan, marking a year-on-year increase of 51.52% [1] - The overall gross margin improved by 1.25 percentage points compared to the same period last year due to a smaller increase in operating costs relative to revenue growth [1] Group 2: Product Performance and Market Expansion - The veterinary chemical drug segment saw continuous sales growth, with the main product, Chlortetracycline, experiencing increased sales in both domestic and international markets [2] - The company expanded its market share and penetration in the domestic market, particularly in the pig farming sector, which has seen improved profitability [2] - The overseas market also showed significant growth, with sales volume doubling in other export markets compared to the previous year [2] Group 3: Vaccine and Pet Business Development - The vaccine segment is gaining market recognition, with the blue ear disease inactivated vaccine achieving a leading market share domestically [2] - The company is actively advancing its pet health business, focusing on pharmaceutical and vaccine products, with plans to launch new products [3] - The veterinary vaccine segment is expected to become a high-growth area, potentially serving as a second growth curve for the company's performance [3]